Role of combined determination of miR-100，miR-148a，β-CTX，tP1NP and BGP in osteoporotic fractures

doi:10.3969/j.issn.1673-8640.2026.08.011

Abstract

Abstract:

Objective To investigate the clinical value of bone metabolism markers [beta-C-terminal telopeptide of type Ⅰ collagen（β-CTX），total type Ⅰ collagen N-terminal propeptide（tP1NP），bone glaprotein（BGP）] and miR-100，miR-148a in the occurrence of osteoporotic fractures（OF）. Methods A total of 167 elderly patients with osteoporosis（OP） and 80 healthy subjects from January 2023 to November 2025 in Kaifeng People's Hospital were enrolled. All the OP patients were classified into fracture group（82 cases） and non-fracture group（85 cases）. Bone mineral density，bone metabolism markers（β-CTX，tP1NP，BGP） and miR-100，miR-148a were determined. Spearman correlation analysis was used to evaluate the correlations among the indicators. Multivariate Logistic regression analysis was used to evaluate the influencing factors of OF. Receiver operating characteristic（ROC） curve was used to evaluate the efficacy of single and combined determinations of each indicator in diagnosing OF. Results The levels of β-CTX，tP1NP，BGP and the relative expression levels of miR-100 and miR-148a in OP group were higher than those in healthy control group（P<0.001）. The levels of β-CTX，tP1NP and BGP were positively correlated with the expression of miR-100 and miR-148a（P<0.001）. The levels of β-CTX，tP1NP，BGP and the relative expression levels of miR-100 and miR-148a in fracture group were higher than those in non-fracture group（P<0.001）. The increase in β-CTX，tP1NP，BGP，miR-100 and miR-148a were risk factors for OF（P<0.05）. The areas under curves（AUC） of β-CTX+tP1NP+BGP，β-CTX+tP1NP+BGP+miR-100，β-CTX+tP1NP+BGP+miR-148a and β-CTX+tP1NP+BGP+miR-100+miR-148a combined determinations for diagnosing OF were 0.899，0.914，0.919 and 0.930，respectively. Conclusions The levels of β-CTX，tP1NP，BGP and the expression of miR-100 and miR-148a are increased in OP patients，and the increase is more significant in OF patients. The combined determination of β-CTX，tP1NP，BGP and miR-100，miR-148a has high clinical efficiency for OF.

Key words: Beta-C-terminal telopeptide of type Ⅰ collagen, Total type Ⅰ collagen N-terminal propeptide, Bone glaprotein, MicroRNA-100, MicroRNA-148a, Osteoporosis, Osteoporotic fracture

CLC Number:

R446.1

LIU Chengguo, LI Yuanyuan, LI Shaowei, CHEN Kai, ZHU Xianyou. Role of combined determination of miR-100，miR-148a，β-CTX，tP1NP and BGP in osteoporotic fractures[J]. Laboratory Medicine, 2026, 41(8): 787-792.

Figures/Tables 8

References 21

[1]	吴芷若, 黄水金, 霍亚南, 等. 骨质疏松症患者脆性骨折危险因素分析及骨折风险评估模型的建立[J]. 中华骨质疏松和骨矿盐疾病杂志, 2024, 17(4):308-317.
[2]	Kahwati L C, Kistler C E, Booth G, et al. Screening for osteoporosis to prevent fractures:a systematic evidence review for the US preventive services task force[J]. JAMA, 2025, 333(6):509-531.
[3]	桂先革, 蒋增辉, 陈标, 等. 骨钙素和Ⅰ型前胶原N端前肽对骨质疏松性椎体压缩性骨折患者术后再骨折的预测价值[J]. 中华老年病研究电子杂志, 2020, 7(1):22-26.
[4]	Bhattoa H P, Cavalier E, Eastell R, et al. IFCC-IOF committee for bone metabolism. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood[J]. Clin Chim Acta, 2021, 515:16-20.
[5]	杨楠, 陈跃平, 章晓云. 分子信号通路及细胞层面的骨折愈合机制[J]. 中国组织工程研究, 2019, 23(20):3188-3194.
[6]	Seeliger C, Karpinski K, Haug A T, et al. Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures[J]. J Bone Miner Res, 2014, 29(8):1718-1728.
[7]	Jones T L, Esa M S, Li K H C, et al. Osteoporosis,fracture,osteoarthritis & sarcopenia:a systematic review of circulating microRNA association[J]. Bone, 2021, 152:116068.
[8]	中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中国全科医学, 2023, 26(14):1671-1691.
[9]	中华医学会骨科学分会. 骨质疏松骨折诊疗指南[J]. 中华骨科杂志, 2008, 28(10):875-878.
[10]	Tang Y, Wei F, Yu M, et al. Absence of causal association between vitamin D and bone mineral density across the lifespan:a Mendelian randomization study[J]. Sci Rep, 2022, 12(1):10408.
[11]	周望展, 何卫, 赵峰. 6项骨代谢标志物与老年骨质疏松性骨折的相关性研究[J]. 中国卫生检验杂志, 2023, 33(16):2012-2014.
[12]	田鹏飞, 陈娟娟, 程娜. β-CTX、T-P1NP及其比值与老年女性骨质疏松相关性[J]. 中国骨质疏松杂志, 2025, 31(5):646-649.
[13]	Al-rawaf H A, Alghadir A H, Gabr S A. Circulating microRNA expression,vitamin D,and hypercortisolism as predictors of osteoporosis in elderly postmenopausal women[J]. Dis Markers, 2021, 2021:3719919.
[14]	Ding W, Ding S, Li J, et al. Aberrant expression of miR-100 in plasma of patients with osteoporosis and its potential diagnostic value[J]. Clin Lab, 2019, 65(9):e10.
[15]	Lincoln S, Morse L R, Troy K, et al. MicroRNA-148a-3p is a candidate mediator of increased bone marrow adiposity and bone loss following spinal cord injury[J]. Front Endocrinol(Lausanne), 2022, 13:910934.
[16]	Yang W, Zhu W W, Yamg Y F, et al. Exosomal miR-100-5p inhibits osteogenesis of hBMSCs and angiogenesis of HUVECs by suppressing the BMPR2/Smad1/5/9 signalling pathway[J]. Stem Cell Research & Therapy, 2021, 12(1):390.
[17]	Dole N S, Yoon J, Monteiro D A, et al. Mechanosensitive miR-100 coordinates TGFβ and Wnt signaling in osteocytes during fluid shear stress[J]. FASEB J, 2021, 35(10):e21883.
[18]	Dai Z, Wei G. Inhibition of miRNA-100 facilitates bone regeneration defects of mesenchymal stem cells in osteoporotic mice through the protein kinase B pathway[J]. Bioengineered, 2022, 13(1):963-973.
[19]	Pan B, Zheng L, Liu S, et al. MiR-148a deletion protects from bone loss in physiological and estrogen-deficient mice by targeting NRP1[J]. Cell Death Discov, 2022, 8(1):470.
[20]	Cheng P, Chen C, He H B, et al. MiR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B[J]. J Bone Miner Res, 2013, 28(5):1180-1190.
[21]	Li Y, Yang S, Wang G, et al. MiR-148a-3p regulates the fracture healing process by targeting MAFB[J]. J Orthop Surg Res, 2025, 20(1):826.

基因名称	上游引物（5'~3'）	下游引物（5'~3'）
miR-100-5p	ACACTCCAGCTGGGAACCCGTAGATCCGAACT	CTCAACTGGTGTCGTGGA
miR-148a-3p	ACACTCCAGCTGGGTCAGTGCACTACAGAACT	CTCAACTGGTGTCGTGGA
U6	CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT

基因名称	上游引物（5'~3'）	下游引物（5'~3'）
miR-100-5p	ACACTCCAGCTGGGAACCCGTAGATCCGAACT	CTCAACTGGTGTCGTGGA
miR-148a-3p	ACACTCCAGCTGGGTCAGTGCACTACAGAACT	CTCAACTGGTGTCGTGGA
U6	CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT

组别	例数	性别		年龄/岁	BMI/（kg·m^-2）	骨密度
组别	例数	男/例	女/例	年龄/岁	BMI/（kg·m^-2）	腰椎/（mg·cm^-2）	髋部/（mg·cm^-2）
OP组	167	48	119	71.00（66.00，75.00）	23.91±1.96	0.58（0.54，0.60）	0.52（0.48，0.54）
正常对照组	80	27	53	70.50（67.00，74.00）	23.68±1.94	0.79（0.76，0.82）	0.73（0.71，0.76）
统计值		0.641		-0.117	-0.844	-12.728	-12.726
P值		0.423		0.907	0.399	<0.001	<0.001

组别	例数	性别		年龄/岁	BMI/（kg·m^-2）	骨密度
组别	例数	男/例	女/例	年龄/岁	BMI/（kg·m^-2）	腰椎/（mg·cm^-2）	髋部/（mg·cm^-2）
OP组	167	48	119	71.00（66.00，75.00）	23.91±1.96	0.58（0.54，0.60）	0.52（0.48，0.54）
正常对照组	80	27	53	70.50（67.00，74.00）	23.68±1.94	0.79（0.76，0.82）	0.73（0.71，0.76）
统计值		0.641		-0.117	-0.844	-12.728	-12.726
P值		0.423		0.907	0.399	<0.001	<0.001

组别	例数	β-CTX/（ng·L^-1）	tP1NP/（ng·mL^-1）	BGP/（ng·mL^-1）	miR-100	miR-148a
OP组	167	629.0 （531.0，703.0）	89.80 （76.80，108.70）	32.20 （26.40，37.30）	1.71 （1.25，2.27）	1.50 （1.10，2.11）
正常对照组	80	422.0 （355.5，507.0）	54.40 （42.18，68.08）	17.10 （12.40，20.78）	0.94 （0.73，1.29）	0.91 （0.61，1.06）
统计值		-9.265	-10.960	-10.673	-7.521	-8.348
P值		<0.001	<0.001	<0.001	<0.001	<0.001